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on the actual outcome of therapy, as the rs12979860 could better
predict RVR, whereas the rs8099917 would be more informative
for SVR. We addressed this point in a subsequent manuscript
where 539 patients of the entire cohort, for whom blood samples
were available, were genotyped for the two SNPs [5]. In our
patients the rs12979860 resulted to have a greater impact of
the rs8099917 for either RVR (OR = 4.69, 95% CI 3.00–7.34 vs.
OR = 3.01, 95% CI 1.97–4.59) and SVR (OR = 5.15, 95% CI 3.32–
7.98 vs. OR = 2.46, 95% CI 1.72–3.51). Moreover, we entered the
two SNPs together with the new ss469415590 dinucleotide vari-
ant (located in IFNL4 gene) into a multiple logistic model and the
hit SNP appeared to be the rs12979860CC genotype, as it was the
only one to retain an independent prediction power for SVR
(OR = 3.39; 95% CI 1.61–7.13). The discrepancy between our data
and the referenced results by Stättermayer et al. [6] could be
explained by differences in the HCV genotypes between patients
enrolled into the two studies: while our data refer to only
patients with HCV-1, the Stättermayer cohort of patients was a
mix population of patients infected by all HCV genotypes.
A further point raised by Dr. Boglione concerns the capability
of predicting SVR in patients with the rs12979860 non-CC type
by determining the TT genotype of the rs8099917. In the accom-
panying Table 1, we stratiﬁed our patients by both genotypes: of
the 420 individuals with non-CC type, SVR rates were docu-
mented in 33% (44/134), 29% (72/250), and 19% (7/36) of subjects
with the rs8099917 subtypes TT, TG or GG, respectively.
While we may agree with our colleagues that monitoring of
ribavirin levels during therapy could also impact positively on
the outcome of therapy, we have not considered this point in
our work.
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To the Editor
Table 1. Genotypes distribution of rs12979860 and rs8099917 SNPs in IL28B locus and Sustained Virological Response (SVR).
rs12979860 
CC SVR (%) CT SVR (%) TT SVR (%) 
rs8099917 
GG 0 0 (0) 3 0 (0) 33 7 (21)
TG 15 7 (47) 208 62 (30) 42 10 (24)
TT 104 74 (71) 118 39 (33) 16 5 (16)
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Open access undeVirtual portal pressure from anatomic CT angiography:
We read with great interest the paper ‘‘Accurate computed
tomography-based portal pressure assessment in patients with
hepatocellular carcinoma’’, which proposed a novel CT-basedJournal of Hepatology 201
r CC BY-NC-ND license.model in the prediction of hepatic venous pressure gradient
(HVPG) [1]. By combining liver/spleen volume ratio and the pres-
ence of peri-hepatic ascites, this non-invasive model had a very
good accuracy in predicting HVPG >10 mmHg [1]. Although HVPG4 vol. 61 j 169–182
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is the most accurate method to evaluate portal hypertension, this
technique is invasive and not routinely performed in all centers.
Therefore, emerging non-invasive techniques have been pro-
posed to measure portal pressure.
More recently, index computed from CT angiography has
created good diagnostic performance compared with ‘‘golden
standard’’. For instance, in the cardiovascular ﬁeld, fractional ﬂow
reserve (FFR) derived from CT angiography (FFRCT) has evolved to
become a potential alternative to FFR, an invasive, lesion-speciﬁc
and well-validated parameter to detect functionally signiﬁcant
coronary artery stenosis. The diagnostic value of FFRCT has
been conﬁrmed by landmark multicenter studies, the DISCOVER-
FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via
Non-invasive Fractional Flow Reserve) study [2] and the DeFAC-
TO (Determination of Fractional Flow Reserve by Anatomic Com-
puted Tomographic AngiOgraphy) trial [3]. Our previous study
also established a novel non-invasive method for quantifying
FFR through three-dimensional modeling from coronary CT data
[4]. All the results mentioned above suggested that non-invasive
assessment of arterial pressure from CT angiography was feasible
and reliable [5].
Like the FFRCT to alternate the invasive procedure of FFR, non-
invasive techniques for evaluating portal hypertension are estab-
lished to replace the invasive procedure. Parameters computed
fromCT angiography are a promising track to follow. The CT-based
model conducted by Iranmanesh et al. is of clinical signiﬁcance
with good performance in prediction of HVPG >10 mmHg, with
sensitivity, speciﬁcity, and positive and negative predictive values
of 92%, 79%, 91%, and 81%, respectively [1]. However, a ﬂaw of the
model, like most of non-invasive methods for assessing portal
pressure, is that it can effectively only identify severe portal hyper-
tension (HVPG >10 mmHg) but with a poor diagnostic perfor-
mance in predicting moderate or mild portal hypertension
(HVPG610 mmHg). The discrimination of prediction performance
between patients with an HVPG> or 610 mmHg might be due to
the presence of peri-hepatic ascites. Therefore, amethod assessing
moderate or mild portal hypertension is still under investigation.
Our preliminary results of the VIRGIN (VIRtual Portal Vein Pres-
sure AGainst INvasive Evaluation) study suggested that the virtual
portal pressure by ﬁnite element analysis and computational ﬂuid
dynamics over three-dimensional CT-model might offer another
prediction of moderate or mild portal hypertension without the
need of invasive measurement [6].
In conclusion, we appreciate the ingenuity of the study by
Iranmanesh et al. The novel assessment will now be optimized
with greater patient numbers and more complex cases. Portal
pressure derived from CT angiography data either formula or
computational ﬂuid dynamics is promising for liberating patients
from invasive procedures.
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